BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/25/2025 4:18:46 PM | Browse: 129 | Download: 715
 |
Received |
|
2024-11-26 06:35 |
|
Peer-Review Started |
|
2024-11-26 06:35 |
|
First Decision by Editorial Office Director |
|
2024-12-12 07:23 |
|
Return for Revision |
|
2024-12-12 07:23 |
|
Revised |
|
2024-12-25 08:32 |
|
Publication Fee Transferred |
|
2025-01-06 06:19 |
|
Second Decision by Editor |
|
2025-02-07 02:36 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-02-07 06:11 |
|
Articles in Press |
|
2025-02-07 06:11 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-03-07 07:49 |
|
Publish the Manuscript Online |
|
2025-03-25 16:18 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Infectious Diseases |
| Manuscript Type |
Retrospective Study |
| Article Title |
Clinical observation of nivolumab combined with cabozantinib in the treatment of advanced hepatocellular carcinoma
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Lu-Wen Liang, Rong-Hong Luo, Zhi-Li Huang and Li-Na Tang |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Rong-Hong Luo, Professor, Department Of Infectious Diseases, The Third Affiliated Hospital of Chongqing Medical University, No. 1 Shuanghu Branch Road, Yubei District, Chongqing 401120, China. loudiudiu2024@163.com |
| Key Words |
Nivolumab; Cabozantinib; Hepatocellular carcinoma; Tumor markers; Immune function |
| Core Tip |
The combination therapy of cabozantinib and nivolumab in advanced hepatocellular carcinoma can upregulate T lymphocyte levels, reduce tumor marker levels, effectively prolong survival time, and has better efficacy than simple control treatment, with good safety. |
| Publish Date |
2025-03-25 16:18 |
| Citation |
Liang LW, Luo RH, Huang ZL, Tang LN. Clinical observation of nivolumab combined with cabozantinib in the treatment of advanced hepatocellular carcinoma. World J Gastrointest Oncol 2025; 17(4): 103631 |
| URL |
https://www.wjgnet.com/1948-5204/full/v17/i4/103631.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v17.i4.103631 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
